-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
We raise our 12-month price target by $40 to $360, reflecting a 13.5x multiple of our 2026 EPS estimate, a small premium to ELV's three-year historical forward average of 12.7x but below the five-year average of 14.1x. We raise our 2026 EPS estimate to $26.77 from $26.05 and lower our 2027 EPS estimate to $29.08 from $29.56. Our negative fundamental outlook for the managed care sub-industry considers elevated medical cost trends, Affordable Care Act (ACA) subsidies expiration, Medicare reimbursement challenges, headwinds for Medicaid membership, and spending under the One Big Beautiful Bill Act (OBBBA). Though we look favorably on the Q1 outperformance and earnings guidance raise, we note that roughly $1.00 of the $1.25 EPS guidance increase (now set at $26.75 or greater) reflects nonrecurring net investment income. Shares yield 2.1%.